GlassScriptPhysician profile
Donovan Matherne
NPI 1285936542
$4,423.67
in general payments reported to CMS, 2019-2025
32 companies · $632 in 2025
The $632 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,356 · 2022: $1,098 · 2023: $617 · 2024: $720 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $708.76 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Abbvie INC. | $666.03 | 2021-2025 | |
| Amgen INC. | $520.53 | 2021-2022 | |
| Abbott Laboratories | $366.67 | 2021-2025 | Proclaim, Eterna |
| Collegium Pharmaceutical, INC. | $318.29 | 2022-2025 | Belbuca, Xtampza |
| Teva Pharmaceuticals USA, INC. | $248.28 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $195.65 | 2021 | |
| Pfizer INC. | $137.13 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.96 | 2022 | |
| Merck Sharp & Dohme LLC | $94.79 | 2021-2023 | Belsomra |
| Valinor Pharma, LLC | $91.68 | 2024-2025 | Movantik |
| Novartis Pharmaceuticals Corporation | $90.42 | 2021 | |
| Almatica Pharma LLC | $90.17 | 2021-2022 | |
| Medtronic, INC. | $82.64 | 2021-2024 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.20 | 2023-2025 | Relistor |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $69.39 | 2023-2025 | Horizant, Horizant |
| Radius Health, INC. | $64.47 | 2021-2023 | |
| Axsome Therapeutics, INC. | $60.24 | 2025 | Symbravo |
| Redhill Biopharma INC. | $49.61 | 2021-2022 | |
| Eisai INC. | $47.55 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $45.21 | 2022-2023 | Seglentis |
| Vertos Medical, INC. | $42.87 | 2023-2024 | Mild Device Kit |
| Relievant Medsystems, INC. | $38.17 | 2022-2023 | Intracept |
| Fidia Pharma USA INC. | $36.21 | 2021-2022 | |
| Averitas Pharma INC. | $27.25 | 2025 | Qutenza |
| Nalu Medical, INC. | $26.95 | 2021-2024 | Nalu Neurostimulation System |
| Lilly USA, LLC | $23.30 | 2021 | |
| Scilex Pharmaceuticals INC. | $20.91 | 2023 | Ztlido |
| Grt US Holding, INC. | $20.52 | 2021 | |
| Advanced Oxygen Therapy INC. | $14.29 | 2024 | Topical Oxygen Chamber For Extremities |
| Arbor Pharmaceuticals, INC. | $14.07 | 2022 | |
| Hydrocision, INC. | $13.46 | 2025 | Tenjet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donovan Matherne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.